The predictive value of the FT3/FT4 ratio for the severity of coronary artery disease in patients with acute coronary syndrome

FT3/FT4 比值对急性冠脉综合征患者冠状动脉疾病严重程度的预测价值

阅读:1

Abstract

BACKGROUND AND AIMS: Thyroid hormones critically regulate cardiovascular homeostasis, with thyroid dysfunction established as an independent risk factor for coronary artery disease. While free triiodothyronine (FT3) to free thyroxine (FT4) ratio reflects peripheral thyroid hormone conversion efficiency, its prognostic utility for anatomical severity of coronary lesions in acute coronary syndrome (ACS) remains undetermined. METHODS AND RESULTS: This observational study enrolled a total of 431 ACS patients who underwent coronary angiography. The anatomical severity of coronary lesions was quantified by SYNTAX score. Patients were stratified into three groups based on tertiles of the FT3/FT4 ratio: T1 (FT3/FT4 ≤0.27, n = 144), T2 (0.27 < FT3/FT4 ≤0.33, n = 144), and T3 (FT3/FT4 >0.33, n = 143). They were further categorized into low-risk (baseline SYNTAX score [bSS] <23) or mid-/high-risk (bSS ≥23) subgroups based on bSS. Compared with the T1 group, patients in the T2 and T3 groups had significantly lower bSS values. Multivariate logistic regression analysis demonstrated that the T3 group had a 53% lower risk of mid-/high-risk SYNTAX scores than the T1 group (odds ratio [OR] 0.470; 95% confidence interval [CI]: 0.227-0.971; P = 0.041). The area under the receiver operating characteristic curve (AUC) for the FT3/FT4 ratio in predicting mid-/high-risk SYNTAX scores was 0.656 (95% CI: 0.587-0.724; P < 0.001). Clinical decision curve analysis confirmed the clinical utility of the FT3/FT4 ratio for this prediction. Additionally, restricted cubic spline analysis revealed a negative dose-response relationship between the FT3/FT4 ratio and SYNTAX scores (non-linear P = 0.017). CONCLUSION: Impaired peripheral thyroid hormone (increased of the FT3/FT4 ratio) conversion efficiency was independently associated with increased coronary anatomical complexity in ACS patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。